Yt90Zevalin Plus CHOP, Z-CHOP
Radioimmunotherapy represents a significant advance over unlabeled immunotherapy for the
treatment of patients with B-cell non-Hodgkin's lymphoma. The radiobiological effects
associated with Yt90-labelled ibritumomab tiuxetan (Zevalin) include the induction of
apoptosis and cell-cycle redistribution.
The response rate tend to be higher in patients who have been treated with fewer prior
therapies and Yt90-labelled ibritumomab tiuxetan may be suitable for use early in the course
Yt90-labelled ibritumomab tiuxetan has less non hematologic toxicity than chemotherapy, with
only minimal alopecia, mucositis, nausea, or vomiting, and a lower incidence of infections.
Yt90-labelled ibritumomab tiuxetan regimen is routinely and safely given in an outpatient
setting and is completed in 7-9 days and is thus more convenient to be used.
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
2-year progression-free survival and overall survival of patients
Udomsak Bunworasate, M.D.
Division of Hematology and Stem Cell Transplant, Department of Medicine, Faculty of Medicine, Chulalongkorn University
Thailand : Thai Food and Drug Administration